...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >A Clinical Review of Statin-Associated Myopathy
【24h】

A Clinical Review of Statin-Associated Myopathy

机译：他汀相关性肌病的临床评价

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Objective: To review the epidemiology, clinical features, proposed mechanisms, risk factors, and management of statin-associated myopathy. Data Sources: Literature searches were conducted in PubMed (1948 to April 2013), TOXLINE, International Pharmaceutical Abstracts (1970 to April 2013), and Google Scholar using the terms statin, hydroxymethylglutaryl-coenzyme A reductase inhibitors, myopathy, myalgia, safety, and rhabdomyolysis. Results were limited to English publications. Study Selection and Data Extraction: All relevant original studies, guidelines, meta-analyses, and reviews of statin-associated myopathy and safety of statins were assessed for inclusion. References from selected articles were reviewed to identify additional citations. Data Synthesis: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors remain one of the most effective medications for reducing low-density-lipoprotein cholesterol. Statins are well tolerated by most patients; however, it is estimated that 10% to 15% of patients develop statin-related muscle adverse effects known as statin-associated myopathy. Although clinicians may be aware of statin-associated myopathy, they may not be aware of its clinical presentation. Providers should assess individual patient risk factors before choosing the appropriate statin. A variety of skeletal muscle aches that may not present as a danger to the patient, may affect patient adherence and quality of life. There are several steps that providers can take to properly treat and manage patients with myalgia complaints. Conclusions: Statin-associated myopathy is a clinical problem that contributes to statin therapy discontinuation. Patients who are statin intolerant may be treated with alternative treatment options such as low-dose statins, switching statins, using alternative dosing strategies in statins with longer half-lives, non-statin lipid-lowering agents, and complementary therapies.
机译：摘要目的：探讨他汀类药物相关肌病的流行病学，临床特征，拟议机制，危险因素和治疗方法。数据来源：文献检索是在PubMed（1948年至2013年4月），TOXLINE，International Pharmaceutical Abstracts（1970年至2013年4月）和Google学术搜索中进行的，它们使用了他汀类药物，羟甲基戊二酰辅酶A还原酶抑制剂，肌病，肌痛，安全性和横纹肌溶解症。结果仅限于英文出版物。研究选择和数据提取：对所有相关的原始研究，指南，荟萃分析和他汀类药物相关的肌病和他汀类药物的安全性进行了评估。审查了来自某些文章的参考文献，以确定其他引文。数据综合：3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂仍然是降低低密度脂蛋白胆固醇最有效的药物之一。大多数患者对他汀类药物耐受良好;但是，据估计有10％至15％的患者会发生与他汀类药物有关的肌肉不良反应，称为他汀类药物相关的肌病。尽管临床医生可能知道他汀类药物相关的肌病，但他们可能不知道其临床表现。提供者应在选择合适的他汀类药物之前评估患者的个别危险因素。可能不会对患者构成危险的各种骨骼肌疼痛可能会影响患者的依从性和生活质量。提供者可以采取几个步骤来正确治疗和管理患有肌痛症的患者。结论：他汀类药物相关的肌病是导致他汀类药物治疗中止的临床问题。他汀类药物不耐受的患者可以接受其他治疗选择，例如低剂量他汀类药物，转换他汀类药物，在半衰期更长的他汀类药物中使用替代剂量策略，非他汀类降脂药和补充疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号